Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Accumulated Expenses data on file, last reported at $946.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 34.41% year-over-year to $946.5 million; the trailing twelve-month figure through Mar 2026 stood at $946.5 million (up 34.41% YoY), and the FY2025 full-year result was $1.1 billion, up 36.1% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $946.5 million, down from $1.1 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.2 billion in Q3 2025 and bottomed at $355.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $713.0 million (2023), against an average of $730.4 million.
• The widest annual swing landed in 2023, when Accumulated Expenses jumped 42.89%; it then advanced 0.76% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $545.5 million in 2022, then soared by 30.72% to $713.0 million in 2023, then increased by 11.32% to $793.7 million in 2024, then jumped by 36.1% to $1.1 billion in 2025, then fell by 12.38% to $946.5 million in 2026.
• The last three Accumulated Expenses figures came in at $946.5 million (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison